Treatment and practical considerations of IgA nephropathy.

Abstract

IgA nephropathy is a common cause of glomerular disease that may result in kidney failure. Until recently, angiotensin blockade using angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) were the main treatment options for patients with IgA nephropathy. Newer drugs such as sodium-glucose co-transporter 2 (SGLT2) inhibitors, endothelin angiotensin receptor antagonists (DEARA), endothelin receptor antagonists (ERA), complement inhibitors, targeted release formulation glucocorticoids, and a proliferation-inducing ligand (APRIL) and B cell activation factor (BAFF) inhibitors have shown promise in reducing proteinuria and delaying the progression of IgA nephropathy. In this review, we will explore the latest pharmacological options, their efficacy, and when they should be considered in adult patients with IgA nephropathy.

Treatment of growth hormone deficiency with long-acting growth hormones in children, adolescents and adults: Clinical evidence and practical considerations
Agnès Linglart, Régis Coutant, Véronique Kerlan +5
Annales d'Endocrinologie = Annals of Endocrinology29 Sep 2026Peer-reviewedCC BYGeneral biology Endocrinology & metabolismHAL
Posterior Circulation Stroke in Patients With Dizziness: Diagnostic Challenges and Practical Considerations for Emergency Care
Andrea L. Klein, Allison N. Seifert, Jonathan A. Edlow +5
Journal of the American College of Emergency Physicians open21 Oct 2026Peer-reviewedCC BYFull textNeurologyEurope PMCEurope PMCPMC
Engaging children, adolescents and young adults living with rare diseases as research partners: practical considerations for meaningful involvement
Maria Cavaller-Belaubi, Elena-Alexandra Tataru, Donato Bonifazi +11
Frontiers in pediatrics16 Oct 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC
Systemic Therapies in Advanced Adrenocortical Carcinoma: Current Standards, Emerging Strategies, and Practical Considerations
Lina Pedraza Sanchez, Prerna Dogra, Elio Monsour +1
Cancers1 Oct 2026Peer-reviewedCC BY 4.0Full textSurgery & anaesthesiaCrossrefEurope PMC
Practical Considerations for the Design, Conduct, and Reporting of Clinical Pharmacokinetic Drug-Drug Interaction Studies in Drug Development.
Thomas M Polasek, John O Miners
Journal of clinical pharmacology1 Nov 2026Peer-reviewedCC BY-NC-NDFull textPharmacology & toxicologyEurope PMCPMC

Cite

BibTeX RIS

BibTeX

@article{sawaf2026treatment,
  title = {{Treatment and practical considerations of IgA nephropathy.}},
  author = {Hanny Sawaf and Junglee Kim and Ali Mehdi and Corey Cavanaugh and Jonathan J Taliercio},
  journal = {Frontiers in medicine},
  year = {2026},
  month = oct,
  doi = {10.3389/fmed.2026.1911077},
  url = {https://europepmc.org/article/MED/42953388},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - Treatment and practical considerations of IgA nephropathy.
AU  - Hanny Sawaf
AU  - Junglee Kim
AU  - Ali Mehdi
AU  - Corey Cavanaugh
AU  - Jonathan J Taliercio
PY  - 2026
DA  - 2026/10/14
JO  - Frontiers in medicine
DO  - 10.3389/fmed.2026.1911077
UR  - https://europepmc.org/article/MED/42953388
AB  - IgA nephropathy is a common cause of glomerular disease that may result in kidney failure. Until recently, angiotensin blockade using angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) were the main treatment options for patients with IgA nephropathy. Newer drugs such as sodium-glucose co-transporter 2 (SGLT2) inhibitors, endothelin angiotensin receptor antagonists (DEARA), endothelin receptor antagonists (ERA), complement inhibitors, targeted release formulation glucocorticoids, and a proliferation-inducing ligand (APRIL) and B cell activation factor (BAFF) inhibitors have shown promise in reducing proteinuria and delaying the progression of IgA nephropathy. In this review, we will explore the latest pharmacological options, their efficacy, and when they should be considered in adult patients with IgA nephropathy.
SN  - 2296-858X
ER  -

Abstract

Related

Cite